BI 765250 / Boehringer Ingelheim - LARVOL DELTA

A Study to Test How Well Different Doses of BI 765250 Are Tolerated by People With a Skin Disease Called Plaque Psoriasis (clinicaltrials.gov) - P1 | N=64 | Completed | Sponsor: Boehringer Ingelheim | Active, not recruiting ➔ Completed

Trial completion • Dermatology • Immunology • Psoriasis

A Study to Test How Well Different Doses of BI 765250 Are Tolerated by People With a Skin Disease Called Plaque Psoriasis (clinicaltrials.gov) - P1 | N=64 | Active, not recruiting | Sponsor: Boehringer Ingelheim | Trial primary completion date: Jun 2025 ➔ Feb 2025 | Recruiting ➔ Active, not recruiting | Trial completion date: Nov 2025 ➔ Feb 2025

Enrollment closed • Trial completion date • Trial primary completion date • Dermatology • Immunology • Psoriasis

A Study to Test How Well Different Doses of BI 765250 Are Tolerated by People With a Skin Disease Called Plaque Psoriasis (clinicaltrials.gov) - P1 | N=80 | Recruiting | Sponsor: Boehringer Ingelheim | Trial completion date: Jun 2025 ➔ Jan 2026 | Trial primary completion date: Jan 2025 ➔ Aug 2025

Trial completion date • Trial primary completion date • Dermatology • Immunology • Psoriasis

A Study to Test How Well Healthy Men Tolerate BI 765250 When Given as an Infusion Into the Vein or as an Injection Under the Skin (clinicaltrials.gov) - P1 | N=139 | Completed | Sponsor: Boehringer Ingelheim | Active, not recruiting ➔ Completed

Trial completion

A Study to Test How Well Healthy Men Tolerate BI 765250 When Given as an Infusion Into the Vein or as an Injection Under the Skin (clinicaltrials.gov) - P1 | N=135 | Active, not recruiting | Sponsor: Boehringer Ingelheim | Recruiting ➔ Active, not recruiting

Enrollment closed

A Study to Test How Well Healthy Men Tolerate BI 765250 When Given as an Infusion Into the Vein or as an Injection Under the Skin (clinicaltrials.gov) - P1 | N=136 | Recruiting | Sponsor: Boehringer Ingelheim | Trial completion date: Nov 2023 ➔ Jun 2024

Trial completion date

A Study to Test How Well Different Doses of BI 765250 Are Tolerated by People With a Skin Disease Called Plaque Psoriasis (clinicaltrials.gov) - P1 | N=70 | Recruiting | Sponsor: Boehringer Ingelheim | Trial completion date: Jul 2024 ➔ Jan 2025

Trial completion date • Dermatology • Immunology • Psoriasis

A Study to Test How Well Different Doses of BI 765250 Are Tolerated by People With a Skin Disease Called Plaque Psoriasis (clinicaltrials.gov) - P1 | N=70 | Recruiting | Sponsor: Boehringer Ingelheim | Not yet recruiting ➔ Recruiting

Enrollment open • Dermatology • Immunology • Psoriasis

A Study to Test How Well Different Doses of BI 765250 Are Tolerated by People With a Skin Disease Called Plaque Psoriasis (clinicaltrials.gov) - P1 | N=70 | Not yet recruiting | Sponsor: Boehringer Ingelheim

New P1 trial • Dermatology • Immunology • Psoriasis